Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Luca Donatelli is active.

Publication


Featured researches published by Luca Donatelli.


Arthritis & Rheumatism | 2009

Circulating Mesenchymal Stem Cells With Abnormal Osteogenic Differentiation in Patients With Osteoporosis

Luca Dalle Carbonare; Maria Teresa Valenti; Mirko Zanatta; Luca Donatelli; Vincenzo Lo Cascio

OBJECTIVE While the role of osteoclasts in bone loss has been well investigated, the involvement of osteoblast-lineage cells has not been completely elucidated. Several genes contribute to normal osteoblastic differentiation from mesenchymal stem cells (MSCs), but an understanding of their role in the pathogenesis of osteoporosis is still lacking. The present study was undertaken to evaluate a possible alteration of osteogenic gene expression as a mechanism contributing to bone loss. METHODS We studied the osteogenic differentiation process in MSCs obtained from the peripheral blood of 31 patients with osteoporosis and 20 normal donors. The cells were evaluated by colony-forming unit-fibroblastic assay and cultured in osteogenic medium to analyze the transcription factors runt-related transcription factor 2 (RUNX-2) and Sp7 and the bone-related genes COL1A1, SPARC, and SPP1 after 3, 8, and 15 days of differentiation. In addition, to determine possible differences between the 2 groups in terms of osteoclastic and osteoblastic activation, we quantified the osteoprotegerin (OPG) and RANKL levels in the supernatants of osteoblastic culture. RESULTS Circulating MSCs were increased in osteoporosis patients compared with normal donors. In contrast, gene expression analysis revealed down-regulation of RUNX2, Sp7, COL1A1, SPARC, and SPP1 in patients with osteoporosis, associated with a lower OPG:RANKL ratio. CONCLUSION These results suggest that an alteration of osteoblastic differentiation may contribute to the pathogenesis of osteoporosis. The noninvasive approach used in the present study could be proposed as a useful tool for studying mesenchymal involvement in bone diseases.


Bone | 2008

Gene expression analysis in osteoblastic differentiation from peripheral blood mesenchymal stem cells

Maria Teresa Valenti; Luca Dalle Carbonare; Luca Donatelli; Francesco Bertoldo; Mirko Zanatta; Vincenzo Lo Cascio

MSCs are known to have an extensive proliferative potential and ability to differentiate in various cell types. Osteoblastic differentiation from mesenchymal progenitor cells is an important step of bone formation, though the pattern of gene expression during differentiation is not yet well understood. Here, to investigate the possibility to obtain a model for in vitro bone differentiation using mesenchymal stem cells (hMSCs) from human subjects non-invasively, we developed a method to obtain hMSCs-like cells from peripheral blood by a two step method that included an enrichment of mononuclear cells followed by depletion of unwanted cells. Using these cells, we analyzed the expression of transcription factor genes (runt-related transcription factor 2 (RUNX2) and osterix (SP7)) and bone related genes (osteopontin (SPP1), osteonectin (SPARC) and collagen, type I, alpha 1 (COLIA1)) during osteoblastic differentiation. Our results demonstrated that hMSCs can be obtained from peripheral blood and that they are able to generate CFU-F and to differentiate in osteoblast and adipocyte; in this study, we also identified a possible gene expression timing during osteoblastic differentiation that provided a powerful tool to study bone physiology.


Cancer Letters | 2009

STEAP mRNA detection in serum of patients with solid tumours

Mt Valenti; L. Dalle Carbonare; Luca Donatelli; Francesco Bertoldo; B. Giovanazzi; F. Caliari; V. Lo Cascio

STEAP was identified by the strategy of suppression subtractive hybridizations in Los Angeles prostate cancer xenografts. It is expressed in prostate and other cancers, and not in most normal tissue; it can be used as a marker to evaluate biological samples from individuals suspected of having a disease associated with STEAP dysregulation, such as cancers, and may provide prognostic information useful in defining appropriate therapeutic options. The aim of this study was to test the STEAP mRNA detection in the serum of patients with different malignant tumours by using Real-Time reverse transcription PCR. The results were compared with biological samples obtained by age-matched non-malignant donors. Our data demonstrated that STEAP mRNA is detectable in serum of patients with different solid tumours whereas it is not amplifiable in non-malignant donors. This marker revealed with the molecular method of quantitative PCR in serum, may be useful to discriminate normal and cancer patients.


Journal of Alzheimer's Disease | 2013

Increased glutaminyl cyclase expression in peripheral blood of Alzheimer's Disease patients.

Maria Teresa Valenti; Silvia Bolognin; Cristina Zanatta; Luca Donatelli; Giulio Innamorati; Maria Pampanin; Gianluigi Zanusso; Paolo Zatta; Luca Dalle Carbonare

N-truncated and N-modified forms of amyloid-β (Aβ) peptide are found in diffused and dense core plaques in Alzheimers disease (AD) brain. Among them, the most abundant N-truncated peptide starts with pyroglutamyl at residue 3 (AβpE3). AβpE3 has increased aggregation potential and toxicity and its abundance has been reported to correlate with the severity of the clinical phenotype in AD patients. N-terminal glutamate conversion generating AβpE3 is catalyzed by glutaminyl cyclase. This enzyme was found to be upregulated in the cortex of patients with AD. In the present study, we investigated glutaminyl cyclase mRNA and protein expression in peripheral blood from AD patients and age-matched controls. Higher levels of glutaminyl cyclase mRNA and protein were present in AD patients compared with controls. Interestingly, we observed a correlation between glutaminyl cyclase expression and the severity of dementia (value of Mini-Mental State Examination). Therefore, we propose glutaminyl cyclase dosage in peripheral blood as a potential biomarker of AD.


Urologic Oncology-seminars and Original Investigations | 2013

Telomerase mRNA detection in serum of patients with prostate cancer

Luca Dalle Carbonare; Adriano Gasparetto; Luca Donatelli; Alessandra Dellantonio; Maria Teresa Valenti

Telomerase functions as a reverse transcriptase enzyme in the process of telomere synthesis and telomerase activity have been detected in a large part of neoplastic tissues, whereas in normal somatic cells they were low or undetectable. The aim of this study was to investigate the telomerase mRNA detection in the serum of patients with a prostate tumor by using real-time reverse transcription PCR. The results were compared with biological samples obtained by age-matched normal donors and by patients with cardiovascular or metabolic diseases. Our data demonstrated that telomerase mRNA is detectable in the serum of patients with prostate cancer whereas it is not amplifiable in normal donors. This marker, assayed with the molecular method of quantitative PCR in serum, may be useful for diagnosing and monitoring prostate cancer patients.


Journal of Bone and Mineral Metabolism | 2012

Runx-2 gene expression is associated with age-related changes of bone mineral density in the healthy young-adult population

Mirko Zanatta; Maria Teresa Valenti; Luca Donatelli; Chiara Zucal; Luca Dalle Carbonare

Bone mineral density (BMD) and peak bone mass (PBM) are important determinants of skeletal resistance. The development of bone densitometry improved the possibility of studying BMD and the influence of genetic and environmental factors on bone. Heredity factors are important for BMD, and Runx-2 is accepted as a regulator of osteoblasts and bone formation. The aim of our study was to evaluate the behavior of Runx-2 during skeletal maturity in the healthy young-adult population. We analyzed spine and hip BMD in 153 volunteers, 98 women and 55 men, using dual-energy X-ray absorptiometry. In a subgroup of these volunteers, a sample of peripheral blood was taken to perform gene expression analysis of Runx-2 both in peripheral mesenchymal stem cells (MSCs; 28 subjects) and in peripheral mononuclear cells (PBMCs; 140 subjects). In our work BMD was comparable in both genders after puberty, then became higher in men than women during the third and fourth decades. PBM was achieved in the third decade in women and in the fourth in men. More interestingly, Runx-2 gene expression highly correlated with BMD in both genders. MSCs and PBMCs showed the same gene expression profile of Runx-2. In conclusion, PBM is reached earlier in females, BMD becomes higher in males later in life, and BMD and PBM are strictly associated with Runx-2. In addition, PBMC should be considered an important source for gene expression analysis in bone diseases.


Journal of Endocrinological Investigation | 2010

Zoledronic acid decreases mRNA six-transmembrane epithelial antigen of prostate protein expression in prostate cancer cells.

Mt Valenti; Sandro Giannini; Luca Donatelli; Giuseppe Realdi; V. Lo Cascio; L. Dalle Carbonare

Background: Zoledronic acid (Zol) is used successfully to inhibit bone resorption in tumor bone disease of various human cancer. Zol inhibits the mevalonate pathway and other potential targets include the inhibition of tyrosine phosphatase activity, disruption of metalloproteinase, secretion and down-regulation of the catalytic subunit of telomerase (hTERT). The six-transmembrane epithelial antigen of prostate protein (STEAP) is a new marker highly expressed at all phases of prostate cancer. Aim: Here, we analyzed for the first time the effect of Zol on STEAP gene expression in prostate cancer cells. Material and methods: We evaluated the effects of Zol in STEAP gene expression by RT real time PCR in androgen-sensitive (LNCaP) and androgen-non-sensitive (PC3 and DU145) cell lines. To confirm the pro-apoptotic effect of Zol, we also analyzed the caspase-3 gene expression, that resulted up-regulated in cancer cell apoptosis. Results: Zol strongly decreased cell viability and lowered STEAP gene expression in a dose-dependent manner. In addition, this effect was accompanied by an increase of apoptotic index and an up-regulation of caspase-3 gene expression. Conclusion: Zol may affect cancer cells also by targeting the gene expression of STEAP.


Arthritis Research & Therapy | 2010

The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation.

Maria Teresa Valenti; Sandro Giannini; Luca Donatelli; Mirko Zanatta; Francesco Bertoldo; Stefania Sella; Maria Teresa Vilei; Elena Ossi; Giuseppe Realdi; Vincenzo Lo Cascio; Luca Dalle Carbonare

IntroductionThe purpose of this study was to evaluate the effects of risedronate (Ris) in the modulation of bone formation in rats with glucocorticoid (GC)-induced osteoporosis by histomorphometric, immunohistochemical and gene expression analyses.MethodsWe analyzed structure, turnover and microarchitecture, cyclooxygenase 2 (COX-2) levels and osteocyte apoptosis in 40 female rats divided as follows: 1) vehicle of methylprednisolone (vGC) + vehicle of risedronate (vRis); 2) Ris 5 μg/Kg + vGC; 3) methylprednisolone (GC) 7 mg/Kg + vRis; 4) GC 7 mg/Kg +Ris 5 μg/Kg. In addition, we evaluated cell proliferation and expression of COX-2 and bone alkaline phosphatase (b-ALP) genes in bone marrow cells and MLO-y4 osteocytes treated with Ris alone or in co-treatment with the selective COX-2 inhibitor NS-398 or with dexametasone.ResultsRis reduced apoptosis induced by GC of osteocytes (41% vs 86%, P < 0.0001) and increased COX-2 expression with respect to controls (Immuno-Hystochemical Score (IHS): 8.75 vs 1.00, P < 0.0001). These positive effects of Ris in bone formation were confirmed by in vitro data as the viability and expression of b-ALP gene in bone marrow cells resulted increased in a dose dependent manner.ConclusionsThese findings suggest a positive effect of Ris in bone formation and support the hypothesis that the up-regulation of COX-2 could be an additional mechanism of anabolic effect of Ris.


The Journal of Clinical Endocrinology and Metabolism | 2012

Runx2 mRNA Expression in the Tissue, Serum, and Circulating Non-Hematopoietic Cells of Patients with Thyroid Cancer

Luca Dalle Carbonare; Anna Chiara Frigo; Giuseppe Francia; Maria Vittoria Davì; Luca Donatelli; Chiara Stranieri; Paolo Brazzarola; Maria Chiara Zatelli; Fabio Menestrina; Maria Teresa Valenti


Anticancer Research | 2014

Ascorbic Acid Induces either Differentiation or Apoptosis in MG-63 Osteosarcoma Lineage

Maria Teresa Valenti; Mirko Zanatta; Luca Donatelli; Gianmaria Viviano; Chiara Cavallini; Maria Teresa Scupoli; Luca Dalle Carbonare

Collaboration


Dive into the Luca Donatelli's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge